Speaker illustration

Doctor Arzu Kalayci Karabay

Harvard Medical School, Boston (United States of America)

Betrixaban versus enoxaparin for venous thromboembolism prophylaxis in critically ill patients: findings from the APEX trial

Event: ESC Congress 2018

Topic: Venous Thromboembolism

Session: Progress in anticoagulation for venous thromboembolism

Thumbnail

Asymptomatic deep vein thrombosis in acutely ill medical patients: insights from the APEX trial

Event: ESC Congress 2018

Topic: Venous Disease

Session: Venous thrombosis and anticoagulation

Thumbnail

ESC 365 is supported by

logo Novo Nordisk